Clinical Trials

The Michigan Medicine Department of Radiation Oncology is a worldwide leader in cancer treatment and research. The novel research studies and clinical trials conducted by our faculty drives discovery and advances our cancer treatment delivery and effectiveness.

To learn more about the studies in Radiation Oncology listed below, please email Jody Sharp or phone 734-615-4909. 

Questions about cancer treatment at Michigan Medicine can also be addressed at the Rogel Cancer Center AnswerLine: (800) 865-1125. To learn more about open clinical trials throughout the Michigan Medicine enterprise, search the Rogel Cancer Center's clinical trials directory. For Oncology-specific trials, go to the Rogel Cancer Center's Oncology Clinical Trials listing.

Highlights

Changing the way oropharyngeal cancer is treated
A trial published in 2010 showed that intensity-modulated chemoradiotherapy can be delivered in such a way as to minimize swallowing difficulty in patients being treated for oropharyngeal cancer. The trial found that this way of delivering therapy did not diminish the effectiveness the treatment. This way of delivering therapy has now become standard practice for treatment of this type of cancer.

  

Changing the way hepatocellular cancer is treated
Our physicians showed in a 2005 trial that hepatocellular cancer can be effectively treated with radiation. Using techniques for dose planning and conformal therapy that were new at the time, our clinicians were able to give high doses of radiation to the tumor which resulted in increased survival.  Building on this trial, our physicians and others have continued to improve and refine the treatment of hepatocellular cancer with radiation.

 

List of Trials

Metastases

UMCC 2018.032: 9979 / HP-00067789: Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Brain

UMCC 2017.094: A Prospective Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma

RTOG 1071 / ALLIANCE N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (Alliance N0577)

Head & Neck

UMCC 2018.085Phase II Trial Of Radiotherapy, Carboplatin/Paclitaxel And Nivolumab For High Risk HPV-Related Oropharynx Cancer

UMCC 2018.070The feasibility of evaluating cervical, thoracic, and scapular dysfunction in head and neck cancer patients

UMCC 2017.113: A Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer

UMCC 2013.062: Randomized Phase II study of DCE-MRI-based dose escalation for poor-prognosis head and neck cancer

NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Breast

MA.39: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer

Lung/Thoracic

UMCC 2018.121: The Selective Personalized Radio-Immunotherapy for locally advanced NSCLC Trial (SPRINT)

UMCC 2015.035: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (R-DART)

Liver/GI

UMCC 2015.039: A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma

UMCC 2003.081: Assessment of Liver Function in Patients Undergoing Hepatic Irradiation

UMCC 2006.067: A Pilot Study of Radiation Toxicity Using MRI-Based Perfusion.

HUM00133653: A Study of Circulating Biomarkers in Hepatocellular Carcinoma

Prostate/GU

UMCC 2018.084: Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): a phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) w/wo neurovascular sparing for erectile function preservation in localized PC

NRG-GU006A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer

UMCC 2017.156: Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide

NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer

NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

GYN

New NRG Study Coming Soon!

Other

UMCC 2012.113: Optimization of MRI for Radiation Therapy

VA Trials

Chapman IRB-2016-353: Randomized Phase II Study of DCE-MRI Based Dose Escalation for Poor-Prognosis Head and Neck Cancer (UMCC 2013.062)

Elliott IRB-2015-350A Pilot Study of Response-Driven Adaptive Radiation Therapy For Patients with Locally Advanced NSCLCa (UMCC 2015.035)

Chapman IRB-2018-1090A Multi-Center Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer (UMCC 2017.113)

Brighton Center for Specialty Care Trials

UMCC 2017.156Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide

NRG-GU006A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer

UMCC 2018.084Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): a phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) w/wo neurovascular sparing for erectile function preservation in localized PC

S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer

UMCC 2017.113A Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer